RAPT Therapeutics (RAPT) News Today $0.95 -0.02 (-2.15%) As of 10:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period RAPT Therapeutics (RAPT) to Release Earnings on ThursdayRAPT Therapeutics (NASDAQ:RAPT) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-rapt-therapeutics-inc-stock/)May 3 at 5:06 AM | marketbeat.comTCG Crossover Management LLC Buys Shares of 13,135,260 RAPT Therapeutics, Inc. (NASDAQ:RAPT)TCG Crossover Management LLC purchased a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,135,260 shareMay 1, 2025 | marketbeat.com1,243,513 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Purchased by Nantahala Capital Management LLCNantahala Capital Management LLC bought a new position in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,243,513 shares of the company's stock, valued at approximApril 30, 2025 | marketbeat.comForesite Capital Management VI LLC Invests $19.75 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)Foresite Capital Management VI LLC acquired a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 12,500,000 shares of the company'sApril 30, 2025 | marketbeat.comIs RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?April 18, 2025 | finance.yahoo.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Short Interest UpdateRAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 4,940,000 shares, an increase of 85.0% from the March 15th total of 2,670,000 shares. Currently, 15.1% of the shares of the company are sold short. Based on an average trading volume of 852,200 shares, the short-interest ratio is presently 5.8 days.April 18, 2025 | marketbeat.comRapt Therapeutics appoints Jessica Savage as VP, clinical developmentApril 17, 2025 | markets.businessinsider.comAffinity Asset Advisors LLC Makes New $1.58 Million Investment in RAPT Therapeutics, Inc. (NASDAQ:RAPT)Affinity Asset Advisors LLC acquired a new stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,000,000 shares of the company's stock, valued at approximately $1April 17, 2025 | marketbeat.comRAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical DevelopmentApril 15, 2025 | markets.businessinsider.comRAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical DevelopmentApril 15, 2025 | globenewswire.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of "Hold" from BrokeragesShares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) have earned an average recommendation of "Hold" from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have given a hold ratingApril 15, 2025 | marketbeat.comADAR1 Capital Management LLC Grows Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)ADAR1 Capital Management LLC raised its stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 15,557.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,174,313 shares of the company's stApril 9, 2025 | marketbeat.comRapt AI and AMD work to make GPU utilization more efficientMarch 27, 2025 | venturebeat.comAdaptimmune Therapeutics (ADAP) Receives a Hold from Wells FargoMarch 21, 2025 | markets.businessinsider.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from AnalystsRAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has received a consensus rating of "Hold" from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation andMarch 20, 2025 | marketbeat.comRAPT Therapeutics to Participate in Upcoming Investor ConferencesMarch 7, 2025 | globenewswire.comRapt Therapeutics reports Q4 EPS ($1.14), consensus (36c)March 6, 2025 | markets.businessinsider.comRAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 6, 2025 | globenewswire.comHanmi Pharmaceuticals reports data from trial of Tivumecirnon for gastric cancerFebruary 18, 2025 | finance.yahoo.comStill Cautious Over RAPT Therapeutics' Fresh Start With RPT904February 16, 2025 | seekingalpha.comRapt Therapeutics files to sell 176.45M shares of common stock for holdersJanuary 23, 2025 | markets.businessinsider.comRAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 9, 2025 | globenewswire.comRapt Therapeutics appoints Lyons-Williams as chair of board of directorsJanuary 7, 2025 | markets.businessinsider.comRAPT Therapeutics Announces Leadership Changes and RealignmentJanuary 7, 2025 | msn.comRAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of DirectorsJanuary 6, 2025 | markets.businessinsider.comRAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of DirectorsJanuary 6, 2025 | globenewswire.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of "Hold" from AnalystsShares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) have been assigned an average recommendation of "Hold" from the thirteen research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have issued a holdJanuary 4, 2025 | marketbeat.comShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Grows By 25.5%RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,720,000 shares, an increase of 25.5% from the November 30th total of 1,370,000 shares. Based on an average trading volume of 2,800,000 shares, the days-to-cover ratio is presently 0.6 days.December 30, 2024 | marketbeat.comNotable analyst calls this week: FREYR Battery, Apple and ServiceNow among top picksDecember 28, 2024 | msn.comRAPT upgraded at H.C. Wainwright on China licensing dealDecember 26, 2024 | msn.comPositive Report for RAPT Therapeutics (RAPT) from H.C. WainwrightDecember 26, 2024 | markets.businessinsider.comHC Wainwright & Co. Upgrades RAPT Therapeutics (RAPT)December 26, 2024 | msn.comRapt Therapeutics upgraded to Buy from Neutral at H.C. WainwrightDecember 26, 2024 | markets.businessinsider.comRAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Buy" at HC WainwrightHC Wainwright upgraded RAPT Therapeutics from a "neutral" rating to a "buy" rating and set a $10.00 price target on the stock in a research report on Thursday.December 26, 2024 | marketbeat.comCautious Hold Recommendation for RAPT Therapeutics Amid Strategic Acquisition and Market UncertaintiesDecember 25, 2024 | markets.businessinsider.comRAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreementDecember 25, 2024 | msn.comRAPT Therapeutics stock rises following licensing deal with JemincareDecember 24, 2024 | in.investing.comRapt Therapeutics price target raised to $6 from $4 at Wells FargoDecember 24, 2024 | markets.businessinsider.comRAPT rockets 180% on licensing deal, $150M private placement (update)December 24, 2024 | msn.comPeninsula drugmaker lands $150 million, food allergy drug to fill pipeline holeDecember 24, 2024 | bizjournals.comRAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE AntibodyDecember 23, 2024 | markets.businessinsider.comRAPT Therapeutics Announces $150 Million Private PlacementDecember 23, 2024 | globenewswire.comRAPT Therapeutics: Hold Rating Amid Strategic Uncertainties and Financial ResilienceNovember 26, 2024 | markets.businessinsider.comRAPT Therapeutics Reprices Underwater Employee Stock OptionsNovember 16, 2024 | markets.businessinsider.comFY2024 Earnings Estimate for RAPT Issued By Leerink PartnrsRAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Equities researchers at Leerink Partnrs boosted their FY2024 EPS estimates for shares of RAPT Therapeutics in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($2.3November 15, 2024 | marketbeat.comRAPT Therapeutics Reports Improved Q3 2024 ResultsNovember 14, 2024 | markets.businessinsider.comWhat is Leerink Partnrs' Estimate for RAPT FY2024 Earnings?RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) - Analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of RAPT Therapeutics in a research report issued to clients and investors on Monday, November 11th. Leerink Partnrs analyst T. Smith now expects thaNovember 14, 2024 | marketbeat.comRAPT Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comRAPT Therapeutics: Strategic Shift to Next-Gen Compounds Boosts Buy Rating Despite Program TerminationNovember 13, 2024 | markets.businessinsider.comRAPT Therapeutics (NASDAQ:RAPT) Receives "Hold" Rating from Stifel NicolausStifel Nicolaus reiterated a "hold" rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday.November 13, 2024 | marketbeat.com Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address RAPT Media Mentions By Week RAPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPT News Sentiment▼1.320.73▲Average Medical News Sentiment RAPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPT Articles This Week▼52▲RAPT Articles Average Week Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mind Medicine (MindMed) News Today Sage Therapeutics News Today Upstream Bio News Today Ginkgo Bioworks News Today ABIVAX Société Anonyme News Today REGENXBIO News Today Precigen News Today Cullinan Therapeutics News Today SIGA Technologies News Today Amylyx Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPT) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RAPT Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RAPT Stock Free RAPT Stock Alerts